Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jason Hsu is Director at Immix Biopharma. OQRO lists 2 transactions filed with the SEC under this name, the latest on Dec 26, 2024, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
As of the latest filing on , Jason Hsu reported holding 893,000 shares of Immix Biopharma (IMMX), worth about $6.43M at the last close of $7 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Immix Biopharma IMMX | 893,000 | 893K direct | $7 | $6.43M | Dec 23, 2024 |
Is this Jason Hsu’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median −19.0 pts vs S&P 500, beat it 0 of 1 time.
Average −19.0 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Dec 26, 2024 to Dec 26, 2024, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.0 pts (median, against the S&P 500).
Immix BiopharmaIMMX
2 disclosures · Dec 2024 · 2 bought
Dec 23, 2024Bought~$88Kdisclosed Dec 26
DetailsOfficial recordDec 20, 2024Bought~$17Kdisclosed Dec 26
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Jason Hsu reported 14 open-market purchases and 0 sales here, 2021 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Jason Hsu bought shares on the open market in 2021, 2023 and 2024, and has not bought since 2024.
Jason Hsu reported 14 open-market purchases and 0 sales since 2021; purchases in 3 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $176K6×6 trades | — |
| 2023 | $492K7×7 trades | — |
| 2021 | $250K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Dec 23, 2024, Jason Hsu reported holding 893,000 shares of Immix Biopharma (IMMX). At the last close of $7 on Nov 17, 2026, that is about $6.43M. This is the stake disclosed in filings, not a net worth.
Jason Hsu bought shares on the open market in 2021, 2023 and 2024, and has not bought since 2024.
In SEC filings since 2021: the latest open-market purchase is from 2024; no open-market sale is on record.
Immix Biopharma (IMMX), from 2021 to 2024: 14 purchases and 0 sales.